At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 10 enrolled
Drug / intervention
Abatacept +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Systemic Sclerosis
In Brief
A Phase 2 clinical trial evaluating Abatacept and Placebo for Scleroderma, Diffuse and Scleroderma, Systemic. Completed, enrolled 10 participants across 1 site.
Detailed Summary
Systemic sclerosis (scleroderma) is an autoimmune connective tissue disease that involves the skin and other internal organs for which there are few effective treatment options. We hypothesize that treatment with abatacept, a new therapy recently approved for the treatment of rheumatoid arthritis, may reduce the progression of skin thickening and fibrosis in people with scleroderma.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsScleroderma, Diffuse, Scleroderma, Systemic
CountriesUnited States
CollaboratorsBristol-Myers Squibb
Timeline
Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2007
Enrollment StartNov 2008
Primary CompletionJun 2011
TodayJul 2026
First PostedMar 2, 2007
Enrollment StartNov 1, 2008
Primary CompletionJun 1, 2011
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 19.3 years ago
Interventions
Abataceptdrug
Placebodrug